Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity
Human Gene Therapy · 2024
DOI: 10.1089/hum.2024.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2024. Verfasst von Jacob A Hoffman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Galactose, Genetic Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Program, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Jacob A Hoffman, James M Wilson
Zitieren
APA
Hoffman, J. A., Denton, N., Sims, J. J., Meggersee, R., Zhang, Z., Olagbegi, K., & Wilson, J. M. (2024). Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity. Human Gene Therapy. https://doi.org/10.1089/hum.2024.050
Vancouver
Hoffman JA, Denton N, Sims JJ, Meggersee R, Zhang Z, Olagbegi K, et al. Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity. Human Gene Therapy. 2024. doi:10.1089/hum.2024.050
BibTeX
@article{Hoffman2024,
author = {Hoffman, Jacob A and Denton, Nathan and Sims, Joshua J and Meggersee, Rosemary and Zhang, Zhe and Olagbegi, Kanyin and Wilson, James M},
title = {Modulation of AAV9 Galactose Binding Yields Novel Gene Therapy Vectors and Predicts Cross-Species Differences in Glycan Avidity},
journal = {Human Gene Therapy},
year = {2024},
doi = {10.1089/hum.2024.050}
}
EUVIMED